MCL1 and cancer: While the exact mechanism by which miR-125b acts in CRC initiation and progression is unclear, different studies have identified the increased presence of miR-125 in breast and liver cancers, suggesting that miR-125-induced inhibition of MCL1 protein may selectively promote apoptosis-resistant cancer cells, which then can have greater metastatic potential than the cancer cells susceptible to apoptosis, in various organs (73).